2026 CES Recap

CES 2026 has come to an end, but our journey of innovation continues.

We sincerely thank everyone who stopped by the Anivance AI booth. The conversations and exchanges we shared with you were among the most valuable and meaningful parts of this experience.

During the exhibition, we were pleased to present our full range of solutions and product offerings. Looking ahead, we remain committed to advancing solutions that align with NAMs methodologies and evolving regulatory frameworks, enabling more precise drug development while reducing unnecessary detours along the way.

We are also proud to congratulate our partners for receiving the first prize in the healthcare pitch at the Swiss Pavilion. As judge Eliad Josephson noted, “Anivance AI is building an advanced digital twin platform that models individual biology, behavior, and longitudinal data to simulate health trajectories and test interventions before they are applied in the real world." This recognition is deeply encouraging for us. Beyond the award itself, it reaffirms that what we are building contributes tangible value and purpose to the advancement of sustainable science for humanity.

At Anivance AI, our ambition goes beyond delivering products and services. We strive to be a problem solving partner that helps address known challenges in drug development, while effectively reducing risks and optimizing costs throughout the process.

If our vision resonates with you or if you would like to learn more about what we are working toward, we invite you to follow Anivance AI on LinkedIn for the latest updates.